DDInter1139 DDInter905
A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.
Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability.
Mefenamic acid {u} (Compound) resembles {v} (Compound) Meclofenamic acid
Meclofenamic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Meclofenamic acid
Meclofenamic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sibutramine
Sibutramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Idelalisib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Niflumic Acid
Niflumic Acid {u} (Compound) resembles {v} (Compound) Leflunomide
Leflunomide {u} may lead to a major life threatening interaction when taken with {v} Idelalisib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Meclofenamic acid
Meclofenamic acid {u} may lead to a major life threatening interaction when taken with {v} Cabozantinib
Cabozantinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Ketoprofen
Ketoprofen {u} (Compound) resembles {v} (Compound) Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Idelalisib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Oxybenzone
Oxybenzone {u} (Compound) resembles {v} (Compound) Ketorolac
Ketorolac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Meclofenamic acid
Meclofenamic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Asparaginase Escherichia coli
Asparaginase Escherichia coli {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Diclofenac
Diclofenac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Citalopram
Citalopram {u} may cause a minor interaction that can limit clinical effects when taken with {v} Idelalisib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Nepafenac
Nepafenac {u} (Compound) resembles {v} (Compound) Ketorolac
Ketorolac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Diclofenac
Diclofenac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cannabidiol
Cannabidiol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Idelalisib
Mefenamic acid (Compound) resembles Meclofenamic acid (Compound) and Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Mefenamic acid (Compound) resembles Meclofenamic acid (Compound) and Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Mefenamic acid (Compound) resembles Niflumic Acid (Compound) and Niflumic Acid (Compound) resembles Leflunomide (Compound) and Leflunomide may lead to a major life threatening interaction when taken with Idelalisib
Mefenamic acid (Compound) resembles Meclofenamic acid (Compound) and Meclofenamic acid may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Mefenamic acid (Compound) resembles Ketoprofen (Compound) and Ketoprofen (Compound) resembles Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Mefenamic acid (Compound) resembles Oxybenzone (Compound) and Oxybenzone (Compound) resembles Ketorolac (Compound) and Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Mefenamic acid (Compound) resembles Meclofenamic acid (Compound) and Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Mefenamic acid (Compound) resembles Diclofenac (Compound) and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Mefenamic acid (Compound) resembles Nepafenac (Compound) and Nepafenac (Compound) resembles Ketorolac (Compound) and Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Mefenamic acid (Compound) resembles Diclofenac (Compound) and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a minor interaction that can limit clinical effects when taken with Idelalisib